LEADER 04362nam 2200709Ia 450 001 9910140843503321 005 20200520144314.0 010 $a1-118-03518-6 010 $a1-282-70769-8 010 $a9786612707698 010 $a0-470-62652-6 010 $a0-470-62651-8 035 $a(CKB)2670000000035070 035 $a(EBL)564932 035 $a(OCoLC)662452551 035 $a(SSID)ssj0000416714 035 $a(PQKBManifestationID)11296960 035 $a(PQKBTitleCode)TC0000416714 035 $a(PQKBWorkID)10422988 035 $a(PQKB)11572832 035 $a(MiAaPQ)EBC564932 035 $a(Au-PeEL)EBL564932 035 $a(CaPaEBR)ebr10411514 035 $a(CaONFJC)MIL270769 035 $a(PPN)19807851X 035 $a(EXLCZ)992670000000035070 100 $a20091223d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aEmerging cancer therapy$b[electronic resource] $emicrobial approaches and biotechnological tools /$fedited by Arsenio M. Fialho, Ananda M. Chakrabarty 210 $aHoboken, N.J. $cWiley$dc2010 215 $a1 online resource (448 p.) 225 1 $aWiley series in biotechnology and bioengineering 300 $aDescription based upon print version of record. 311 $a0-470-44467-3 320 $aIncludes bibliographical references and index. 327 $aEMERGING CANCER THERAPY; CONTENTS; PREFACE; CONTRIBUTORS; PART I: LIVE/ATTENUATED BACTERIA AND VIRUSES AS ANTICANCER AGENTS; 1: SALMONELLA TYPHIMURIUM MUTANTS SELECTED TO GROW ONLY IN TUMORS TO ERADICATE THEM IN NUDE MOUSE MODELS; 2: THE USE OF LIVING LISTERIA MONOCYTOGENES AS AN ACTIVE IMMUNOTHERAPY FOR THE TREATMENT OF CANCER; 3: BACILLUS CALMETTE-GUERIN( BCG ) FOR UROTHELIAL CARCINOMA OF THE BLADDER; 4: LIVE CLOSTRIDIA : A POWERFUL TOOL IN TUMOR BIOTHERAPY; 5: BIFIDOBACTERIUM AS A DELIVERY SYSTEM OF FUNCTIONAL GENES FOR CANCER GENE THERAPY 327 $a6: REPLICATION-SELECTIVE VIRUSES FOR THE TREATMENT OF CANCER7: ENGINEERING HERPES SIMPLEX VIRUS FOR CANCER ONCOLYTIC VIROTHERAPY; PART II: BACTERIAL PRODUCTS AS ANTICANCER AGENTS; 8: PROMISCUOUS ANTICANCER DRUGS FROM PATHOGENIC BACTERIA: RATIONAL VERSUS INTELLIGENT DRUG DESIGN; 9: ARGININE DEIMINASE AND CANCER THERAPY; 10: CYTOSINE DEAMINASE/5-FLUOROCYTOSINE MOLECULAR CANCER CHEMOTHERAPY; 11: BACTERIAL PROTEINS AGAINST METASTASIS; 12: PSEUDOMONAS EXOTOXIN A-BASED IMMUNOTOXINS FOR TARGETED CANCER THERAPY; 13: DENILEUKIN DIFTITOX IN NOVEL CANCER THERAPY 327 $a14: THE APPLICATION OF CATIONIC ANTIMICROBIAL PEPTIDES IN CANCER TREATMENT: LABORATORY INVESTIGATIONS AND CLINICAL POTENTIAL15: PRODIGININES AND THEIR POTENTIAL UTILITY AS PROAPOPTOTIC ANTICANCER AGENTS; 16: FARNESYLTRANSFERASE INHIBITORS OF MICROBIAL ORIGINS IN CANCER THERAPY; 17: THE USE OF RNA AND CpG DNN AS NUCLEIC ACID-BASEDTHERAPEUTICS; PART III: PATENTS ON BACTERIA/BACTERIAL PRODUCTS AS ANTICANCER AGENTS; 18: THE ROLE AND IMPORTANCE OF INTELLECTUAL PROPERTY GENERATION AND PROTECTION IN DRUG DEVELOPMENT; INDEX 330 $aExplores current and emerging applications of microbes as cancer-fighting agents Today, treatment options for cancer patients typically include surgery, radiation therapy, immunotherapy, and chemotherapy. While these therapies have saved lives and reduced pain and suffering, cancer still takes millions of lives every year around the world. In recent years, researchers have been working on a new strategy: developing microbes and microbial products that specifically attack cancer cells. This book breaks new ground in emerging cancer treatment modalities by presenting recent advances i 410 0$aWiley series in biotechnology and bioengineering. 606 $aCancer$xTreatment 606 $aViruses$xTherapeutic use 606 $aBacteria$xTherapeutic use 606 $aMicrobial biotechnology 615 0$aCancer$xTreatment. 615 0$aViruses$xTherapeutic use. 615 0$aBacteria$xTherapeutic use. 615 0$aMicrobial biotechnology. 676 $a616.99/406 701 $aFialho$b Arsenio$0859626 701 $aChakrabarty$b Ananda M.$f1938-$0859627 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910140843503321 996 $aEmerging cancer therapy$91918434 997 $aUNINA